Moleculin Biotech, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-33.6M | $-26.0M | $-29.8M | $-29.0M | $-15.9M | $-17.4M | $-13.2M | $-11.9M |
| Depreciation & Amortization | $90.0K | $126.0K | $127.0K | $130.0K | $164.0K | $200.0K | $199.0K | $68.0K |
| Depreciation | $100.0K | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $1.7M | $1.7M | $2.0M | $2.3M | $2.4M | $1.7M | $1.5M | $1.1M |
| Net Cash from Operating Activities | $-22.7M | $-23.9M | $-23.6M | $-27.6M | $-19.0M | $-17.8M | $-17.2M | $-12.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $13.0K | $124.0K | $67.0K | $19.0K | $376.0K | $52.0K | $417.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $0 | $-13.0K | $-124.0K | $-67.0K | $-19.0K | $-374.0K | $-51.0K | $-417.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $27.3M | $4.6M | $4.1M | $-23.0K | $74.7M | $22.5M | $20.9M | $12.0M |
| Net Change in Cash | $4.6M | $-19.3M | $-19.6M | $-27.8M | $55.7M | $4.4M | $3.6M | $-580.0K |
| Free Cash Flow | $-22.7M | $-23.9M | $-23.7M | $-27.7M | $-19.0M | $-18.1M | $-17.3M | $-12.6M |